GlassScriptPhysician profile
Samantha M Hoffman
NPI 1144869397
$2,470.38
in general payments reported to CMS, 2019-2025
24 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $367 · 2023: $653 · 2024: $867 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,982.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,981.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $591.64 | 2022-2025 | |
| Abbott Laboratories | $338.88 | 2023 | Optis, Gallant |
| Medtronic, INC. | $290.81 | 2023-2024 | Onyx Frontier, Linq II |
| Amgen INC. | $135.04 | 2021-2022 | |
| Renalytix Ai, INC. | $117.76 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Novo Nordisk INC | $114.85 | 2021-2024 | Wegovy |
| Edwards Lifesciences Corporation | $106.17 | 2023 | Sapien 3 Ultra Resilia |
| Lilly USA, LLC | $104.19 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $97.78 | 2022-2024 | |
| Baxter Healthcare | $78.38 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $74.42 | 2021-2024 | Xarelto |
| Heartflow, INC. | $69.25 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $67.63 | 2024 | Verquvo |
| Kowa Pharmaceuticals America, INC. | $44.36 | 2021-2022 | |
| Smith+Nephew, INC. | $43.11 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $36.45 | 2025 | |
| Exact Sciences Corporation | $24.96 | 2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $24.32 | 2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $21.49 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $20.69 | 2024 | Rexulti |
| Bausch Health US, LLC | $19.92 | 2024 | Aplenzin |
| Electromed, INC. | $19.35 | 2023 | Smartvest |
| Esperion Therapeutics, INC. | $15.87 | 2023 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samantha Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.